Asir
· 18 retained evidence mentions
Source-grounded findings
Supporting evidence
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| population | Asir | “This study integrates PRISMA, ASTER, and Sentinel-2 remote sensing data with structural analysis, petrography, whole-rock geochemistry, fire assay, and C-O stable isotope data to develop a deformation-controlled mineralization model for the Wadi Al Awja district, Asir terrane.” | 0.80 | saudi_context_rules_v1 |
| population | Asir | “Emerging therapies such as antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) directed against ApoC-III (volanesorsen, olezarsen, and plozasiran), inhibitors of ANGPTL3 (evinacumab and zodasiran), and fibroblast growth factor 21 (FGF-21) analogs (pegozafermin) have demonstrated substantial triglyceride-lowering efficacy.” | 0.80 | saudi_context_rules_v1 |
| population | Asir | “Results: The proposed framework was evaluated on curated upper- and lower-GI tract subsets of the HyperKVASIR dataset under realistic non-IID federated conditions.” | 0.80 | saudi_context_rules_v1 |
| population | Asir | “In the World Bank low-income group, where a low age-standardised incidence rate (ASIR) was estimated (44·2 per 100 000 person-years [31·2 to 58·4]), the age-standardised mortality rate (ASMR) was the highest (24·1 per 100 000 [16·8 to 31·9]). The highest ASIR was in the high-income group (75·7 per 100 000 [67·1 to 84·0]), and the lowest ASMR was in the upper-middle-income group (11·2 per 100 000 [10·2 to 12·3]). Between 1990 and 2023, the ASIR in the low-income group increased by 147·2% (38·1 to 271·7), compared with a 1·2% (-11·5 to 17·2) change in the high-income group.” | 0.80 | saudi_context_rules_v1 |
| population | Asir | “Hidden in CAKUT: Post-Transplant Diagnosis of Primary Hyperoxaluria Type 1 and Rescue Management Using Lumasiran. Lumasiran, a novel RNA interference (RNAi) therapeutic for PH1, was recently discovered with promising results. METHODS: This report describes a pediatric case of PH1 diagnosed post-kidney transplantation with graft dysfunction who was treated with extensive hemodialysis and lumasiran as rescue therapy. RESULTS: Patient was able to stop hemodialysis with the improvement of her kidney function and plasma oxalate after the fourth dose of lumasiran. It also demonstrates the potential efficacy of lumasiran in managing PH1 post-transplantation when combined with intensive hemodialysis and supportive care. However, more studies with prolonged follow-up periods are necessary to establish the long-term efficacy and safety of lumasiran in the treatment of PH1 without the requirement for liver transplantation.” | 0.80 | saudi_context_rules_v1 |
| population | Asir | “Antisense oligonucleotides (e.g., pelacarsen), small-interfering RNAs (e.g., olpasiran, lepodisiran, and zerlasiran), and oral small-molecule Lp(a) inhibitors (e.g., muvalaplin) have demonstrated profound reductions in circulating Lp(a) concentrations, typically achieving decreases of 80-90%.” | 0.80 | saudi_context_rules_v1 |
| population | Asir | “The present study examined the effectiveness of nigella Sativa and manuka honey combination or manuka honey alone to the conventional therapy (Deferasirox + blood transfusion) used for preventing and managing iron overload in pediatric β-thalassemia major patients.” | 0.80 | saudi_context_rules_v1 |
| population | Asir | “The Kvasir dataset was used to thoroughly test the proposed deep learning model.” | 0.80 | saudi_context_rules_v1 |
| population | Asir | “The Kvasir dataset, comprising images of normal Z-line, normal pylorus, ulcerative colitis, stool, and polyps, was used.” | 0.80 | saudi_context_rules_v1 |
| population | Asir | “Three investigational compounds targeting Lp(a), including small interfering RNA (siRNA) agents (olpasiran, SLN360) and an antisense oligonucleotide (pelacarsen), are in various stages of development.” | 0.80 | saudi_context_rules_v1 |
| population | Asir | “Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis. OBJECTIVES: To examine the efficacy of deferasirox (DFX) by comparison with deferoxamine (DFO) in managing iron overload in patients with sickle cell anaemia (SCA).” | 0.80 | saudi_context_rules_v1 |
| population | Asir | “Perforated duodenal ulcer secondary to deferasirox use in a child successfully managed with laparoscopic drainage: A case report. Deferasirox, an iron chelating agent, has been previously reported to be associated with the development of gastroduodenal ulcers. CASE SUMMARY: We report a case of a 3-year-old boy who was diagnosed with beta thalassemia major and treated with deferasirox. CONCLUSION: Due to the rarity and severity of this case, it is a reminder that prevention and early recognition of gastrointestinal complications in patients receiving deferasirox are crucial.” | 0.80 | saudi_context_rules_v1 |
| population | Asir | “Deferasirox and vitamin D3 co-therapy mitigates iron-induced renal injury by enhanced modulation of cellular anti-inflammatory, anti-oxidative stress, and iron regulatory pathways in rat. AIMS: To measure the alleviating effects of deferasirox (DFX) and/or vitamin D (VD) single and combined therapies against nephrotoxicity induced by chronic iron overload.” | 0.80 | saudi_context_rules_v1 |
| population | Asir | “Consistent with a molecular mechanism based on intracellular iron chelation, we observed that deferasirox, a clinically licensed iron chelator able to permeate into cells, also enhanced erythropoiesis in our DBA iPSC model.” | 0.80 | saudi_context_rules_v1 |
| population | Asir | “Juvenile Hemochromatosis: Rheumatic Manifestations of 2 Sisters Responding to Deferasirox Treatment. We report two sisters who presented to the rheumatology clinic with arthralgia, which was subsequently found to have a homozygous mutation variant of unknown significance in the HFE2 gene: c.497A>G;p.(His166Arg) and has been treated with deferasirox (Exjade®).” | 0.80 | saudi_context_rules_v1 |
| population | Asir | “Chelation of endolysosome iron with deferoxamine (DFO) and 2-2 bipyridyl, but not chelation of cytosolic iron with deferiprone and deferasirox, significantly enhanced Tat-mediated HIV-1 LTR transactivation.” | 0.80 | saudi_context_rules_v1 |
| population | Asir | “The link to download BMT is https://github.com/nasiriqbal012/BMT_SETUP.git.” | 0.80 | saudi_context_rules_v1 |
| population | Asir | “BACKGROUND: To compare the efficacy and safety of desferrioxamine (DFO), deferiprone (DFP), deferasirox (DFX) and silymarin in patients with either thalassemia or sickle cell disorder through network meta-analysis.” | 0.80 | saudi_context_rules_v1 |